厄贝沙坦治疗非瓣膜病充血性心力衰竭临床评价

IRBESARTAN IN NONVALVULAR CONGESTIVE HEART FAILURE

目的探讨厄贝沙坦治疗充血性心力衰竭的临床疗效及安全性。方法采用随机、单盲、自身对照及组间对照方法。观察组52例,服用厄贝沙坦,平均(75±15)mg╱d,对照组37例。疗程均为6个月。观察二组治疗前后临床疗效:左室射血分数(LVEF)、左室舒张末期容积(LVEDV)、左室收缩末期容积(LVEDV),6min步行试验及心肌耗氧量。结果其相关参数差异均有高度显著性(P<0.01)。观察组再住院率及病死率明显减少(P<0.025)。二组治疗前后及组间比较肾功能、血糖、血脂、血钾的差异均无显著性(P>0.05)。结论 厄贝沙坦治疗非瓣膜病充血性心力衰竭临床疗效显著且安全,值得临床推广使用。

Objective To observe the effect of irbesartan on patients with nonvalvular congestive heart failure. Methods We divided 100 patients with congestive heart failure into irbesartan group(n = 52) and control group(n = 37) by randomly, single blind contrast trial. Evaluation of clinical effect as LVEF, LVEDV, LVESV, 6 - min walk - trial and the other biochemistry parameters were measured. Results Clinical prognosis of patients in irbesartan group was better than that in control group. LVEF, LVEDV, LVESV and 6 - min walk - trail of patients in irbesartan group all showed significances compared with those of before treatment or in control group or after treatment(P < 0. 01). No significant difference in biochemistry Parameters could be found between two groups(P>0.05). Conclusion Irbesartan is effective in congestive heart failure and is valuable to be popularized in clinic.